Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02452359
Recruitment Status : Terminated (Continuing the trial was considered to be superfluous.)
First Posted : May 22, 2015
Results First Posted : November 3, 2020
Last Update Posted : November 3, 2020
Sponsor:
Information provided by (Responsible Party):
Venus Concept

Brief Summary:
This trial is intended to evaluate the effect of IPL treatment on the Striae Distensae. The study hypothesis is that the SR580 applicator will improve the appearance of Striae Distensae by at least 1 point on the Global Aesthetic Improvement ScaleI (GAIS) at 3 months follow-up compared to baseline in at least 50% of the study population.

Condition or disease Intervention/treatment Phase
Striae Distensae Device: Venus Versa Not Applicable

Detailed Description:

Study Design This is a multi-site, prospective, open labeled clinical trial with before-after study design. This study will include up to 8 visits at the clinic: initial screening/consultation, 5 treatments, visits in 2 week intervals, and 2 follow-up visits at 1 and 3 months after the last treatment visit.

Up to 60 healthy subjects age 24-65 with Striae Distensae will be enrolled.

Study duration:

Duration of subject's participation: Up to 5.5 months from enrollment to termination

Blinding Objective assessment of clinical improvement by global assessment scale will be achieved by sending before/after pictures (baseline/3months after last treatment) to 3 blinded reviewers at the end of the study.

Study Procedures Test Spots Up to 3 test spots will be performed in the selected treatment area to determine the optimal parameters / settings

Treatment visits Each subject will be enrolled and scheduled for 5 treatments at 2 week intervals and return for follow-up visits at one month and 3 months after the last treatment for evaluation of the treated areas. The duration of the entire treatment visit is approximately 60 minutes.

Treatment The treatment areas are divided into 2 treatment areas: abdomen or thighs. Apply a thin layer of IPL gel. Place the applicator in close contact, perpendicular to the skin with no pressure applied. Pressing the applicator will fire the IPL pulse.

Administer pulses throughout the treated area to ensure full coverage of the treated area with applicator overlap approximately 1/3 of the previously treated skin.

A single pass over the area is completed Remove the remnants of the IPL gel and dry thoroughly. Cold air or cold, wet but not frozen gauze pads may be placed on the treated area for post treatment cooling.

Typical responses to the treatment are mild erythema and edema.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label study where all subjects assigned to receive 5 treatments every 2 weeks. Subjects acted as their own control.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Venus Versa SR Applicator Using Intense Pulsed Light on Skin Texture for Improving the Appearance of Striae Distensae
Actual Study Start Date : March 13, 2015
Actual Primary Completion Date : February 15, 2017
Actual Study Completion Date : March 31, 2017

Arm Intervention/treatment
Experimental: Treatment Group
Group receiving treatment with Venus Versa IPL energy
Device: Venus Versa
The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.




Primary Outcome Measures :
  1. Improvement in Striae Distensae Appearance [ Time Frame: 90 days following last IPL treatment ]
    Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   24 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able to provide written Informed Consent;
  2. Healthy male or female, 24-65 years Fitzpatrick-Goldman skin type I-V;
  3. Having visible Striae Distensae to be treated (abdomen/thighs);
  4. Comply with the treatment/follow-up schedule and requirements;
  5. Women of child-bearing age are required to be using a reliable method of birth control

Exclusion Criteria:

  1. Fitzpatrick-Goldman skin type VI;
  2. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after breastfeeding;
  3. Heavy smoker
  4. Unable or unlikely to refrain from tanning
  5. Use of photosensitive medication
  6. Use of oral isotretinoin within 3 months
  7. Any dermal/epidermal damage or disorder in treated area
  8. Prior treatment in treated area within 3 months
  9. Prior skin laser/light or another device treatment in treated area within 6 months
  10. Prior use of collagen, fat injections or other methods of skin augmentation in treated area within 12 months
  11. Prior use of Botox in treatment area within 6 months
  12. Prior ablative resurfacing procedure with laser in treatment area within 12 months
  13. Any other surgery in treated area within 9 months
  14. Participation in a study of another investigational device or drug as per the Investigator's discretion
  15. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
  16. Showing symptoms of hormonal disorders (such as Melasma, Chloasma);
  17. Concurrent inflammatory skin conditions, open laceration or abrasion of any sort on area to be treated during the course of treatment
  18. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study
  19. Multiple dysplastic nevi in area to be treated
  20. Having a bleeding disorder or taking anticoagulation medications
  21. History of immunosuppression/immune deficiency disorders
  22. Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer
  23. Pigmented lesion in the treated area that appears cancerous
  24. Significant concurrent illness, such as uncontrolled diabetes
  25. Active infections in the treated area

28.Tattoo or permanent makeup at the treatment area. 29.Mentally incompetent, prisoner or evidence of active substance or alcohol abuse 30.Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02452359


Locations
Layout table for location information
United States, California
Rosenberg Plastic Surgery
Beverly Hills, California, United States, 90211
Sponsors and Collaborators
Venus Concept
Investigators
Layout table for investigator information
Study Director: Tracey L Mancuso Venus Concept
  Study Documents (Full-Text)

Documents provided by Venus Concept:
Layout table for additonal information
Responsible Party: Venus Concept
ClinicalTrials.gov Identifier: NCT02452359    
Other Study ID Numbers: CS0315
First Posted: May 22, 2015    Key Record Dates
Results First Posted: November 3, 2020
Last Update Posted: November 3, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Venus Concept:
stretch marks
Additional relevant MeSH terms:
Layout table for MeSH terms
Striae Distensae
Skin Manifestations